ViGenCell, Inc.

ViGenCell, Inc.

KKRX:308080
4,395.00
KRW
+120.00
(+2.81%)
-647.62EPS
128.12BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
63.43
0.8
- -
- -
- -
- -
14.5
1.12
44.98
Basic EPS, GAAP
-2,431
-12,604
-1,188.98
-1,012.5
-323
-916
-937
-730.84
-807
-647.62
Free Cash Flow per Basic Share
-1,932.15
-3,557.64
-209.15
-965.24
-681.45
-1,304.66
-853.97
-572.37
-723.8
-562.77
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
103.95
-236.83
-1,341.98
-1,806.11
5,554.16
4,716.53
3,730.05
3,012.18
2,132.77
1,892.3
Tangible Book Value per Share
93.25
-274.87
-1,379.33
-1,877.23
5,466.14
4,637.68
3,636.25
2,934.54
2,081.78
1,848.01
Basic Weighted Avg Shares
- -
1
19
10
34
19
19
19
20
20
Sales/Revenue/Turnover
- -
33
15
- -
- -
- -
- -
279
23
922
Operating Margin (%)
- -
-3,939.6
-32,962.44
- -
- -
- -
- -
-5,495.85
-75,453.12
-1,533.39
Depreciation Expense
54
65
197
881
1,718
2,918
4,098
3,631
2,976
2,825
Net Income, GAAP
-1,034
-6,507
-22,430
-10,455
-11,114
-17,393
-17,875
-14,056
-16,322
-13,275
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-19,871.71
-149,218.83
- -
- -
- -
- -
-5,038.79
-71,986.44
-1,439.86
Working Capital
1,721
-5,674
-26,660
-38,654
56,534
61,539
45,968
37,875
32,494
28,809
LT Debt
- -
- -
- -
328
9
- -
32
262
7,400
7,400
Total Equity
1,961
-4,468
-25,316
-34,072
104,887
89,643
71,489
58,026
43,720
38,791
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
-17.88
-22.19
-21.7
-32.08
-29.38

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
31
20
9
LT Borrowings
7,400
7,400
7,400
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
199,868
110,081
128,120

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
34,201
32,393
30,828
Cash, Cash Equivalents & STI
33,383
31,452
29,554
Accounts Receivable, Net
3
312
641
Inventories
- -
12
12
Total Current Liabilities
1,707
1,706
2,019
Payables & Accruals
- -
- -
- -
ST Debt
31
20
9
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-97.22%
-24.65%
Free Cash Flow
- -
21.45%
32.99%
Net Income, GAAP
- -
12.07%
16.13%
Sales/Revenue/Turnover
- -
- -
-91.87%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
55
1
223
279
2025
- -
1
8
14
23
2026
329
571
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-212
-160.67
-167.38
-190.59
-730.84
2025
-131.9
-264
-109.57
-297.82
-807
2026
-126.21
-114
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Pyung-suk Ki
Full Time Employees
43
Sector
Health technology
Industry
Biotechnology
Address
Seoul South Korea
IPO Date
Aug 25, 2021
Business
ViGenCell, Inc. is a South Korea-based clinical-stage biotechnology company that develops and commercializes advanced immune cell therapies and cellular immunotherapies for the treatment of oncology and intractable immune-mediated diseases. Founded in 2013 and headquartered in Seoul, South Korea, the company operates as an affiliate of Boryung. ViGenCell develops proprietary therapeutic candidates across three primary technology platforms: the ViTier platform, an antigen-specific cytotoxic T-lymphocyte technology utilized for customized cancer immunotherapies, including VT-EBV-N for Epstein-Barr virus-positive natural killer/T-cell lymphoma and VT-Tri(1)-A for acute myeloid leukemia; the ViMedier platform, a cord blood-derived myeloid suppressor cell technology engineered to suppress abnormal immune reactions, including VM-GD (VM-001) for graft-versus-host disease and VM-AD for atopic dermatitis; and the ViRanger platform, an allogeneic universal T-cell gene therapy technology designed for off-the-shelf mass production, including gamma-delta T-cell and chimeric antigen receptor constructs as well as co-developed induced pluripotent stem cell-derived CAR-NK cell therapies such as TB-420 for hepatocellular carcinoma and TB-302 for glioblastoma. In addition, the company operates an advanced biopharmaceutical Good Manufacturing Practice facility, the V-Cell Center, supporting cell processing, clinical batch manufacturing, and contract development and manufacturing capabilities. In recent developments, ViGenCell secured regulatory certification for its V-Cell Center GMP cell processing facility, establishing full-scale in-house manufacturing and supply capabilities. The company initiated patient treatments for lead candidate VT-EBV-N under South Korea's advanced regenerative medicine statutory framework for lymphoma patients in complete remission who face high relapse risks, following the presentation of four-year follow-up Phase 2 clinical data at the American Society of Clinical Oncology Annual Meeting that demonstrated a 100 percent overall survival rate and a 95 percent disease-free survival rate. ViGenCell has also expanded strategic co-development and manufacturing agreements with Therabest for iPSC-derived CAR-NK therapeutic pipelines and strengthened executive management across GMP operations and corporate business development to accelerate pipeline commercialization.